What Is MGF Peptide?
MGF peptide, short for mechano growth factor peptide, is a name used for research compounds connected with one form of the insulin-like growth factor 1 gene. It is often discussed as though it were one clearly defined medicine. It is not. The name can refer to the IGF-1Ec gene transcript, the longer protein made from that transcript, or a short synthetic peptide copied from its unique tail.
That naming problem affects almost every claim made about MGF. Human exercise studies usually measured messenger RNA from the IGF-1Ec transcript in muscle biopsies. Messenger RNA, shortened to mRNA, is a temporary molecular copy that cells use when making a protein. Laboratory studies often added a synthetic 24 or 25-amino-acid tail peptide to cells. Some animal studies used that short peptide, while an analytical paper examined a much larger protein sold as full-length MGF. These materials are related, but they are not interchangeable.
The human evidence does not show what happens when an MGF peptide product is administered to people. It shows that IGF-1Ec-related gene expression can change in skeletal muscle after some forms of exercise or muscle damage. Cell and animal experiments provide possible explanations, including effects on immature muscle cells, cell movement and tissue repair. They cannot establish that an injected research peptide builds muscle, heals injuries or improves recovery in people.
MGF is not an approved medicine. It is also not the same as growth hormone, mature IGF-1 or PEG-MGF. Understanding how peptides are named helps, but MGF also requires careful attention to genes, RNA, precursor proteins and synthetic fragments.
Why does the name MGF cause confusion?
Three related things are commonly called MGF:
- IGF-1Ec mRNA. This is one messenger-RNA transcript created when the IGF1 gene is spliced in a particular way. In human nomenclature it is usually called IGF-1Ec. The comparable rodent transcript has often been called IGF-1Eb.
- The IGF-1Ec precursor protein. A precursor is a larger protein that may be cut and processed before its final products are available. IGF-1Ec contains the mature 70-amino-acid IGF-1 sequence plus an extension called an E-domain.
- A synthetic MGF E peptide. This is usually a laboratory-made chain copying 24 or 25 amino acids from the unique end of the Ec E-domain. Papers use labels such as MGF-Ct24E and MGF-C25E for particular constructs.
Splicing is the editing process that removes non-coding sections from a new RNA copy and joins selected coding sections together. Alternative splicing allows one gene to produce more than one RNA transcript. An isoform is one of the related molecular forms produced in this way.
The word MGF was introduced to describe an IGF-1 form whose expression changed after mechanical loading. Over time, the same name spread to the predicted E-domain product and then to commercial research peptides. A study that measures IGF-1Ec mRNA therefore does not prove that a short MGF peptide entered the blood, reached another tissue or produced an anabolic effect.
Even the short peptide is not represented consistently. Some papers studied 24 residues from the human sequence. Others used a 25-residue construct. Full-length products can include mature IGF-1 and part or all of the E-domain. A vial labelled MGF cannot be identified from the name alone.
How does the IGF-1 system normally work?
Insulin-like growth factor 1, shortened to IGF-1, is a hormone and local signalling protein involved in normal growth, metabolism and tissue maintenance. Growth hormone from the pituitary gland encourages the liver and other tissues to make IGF-1. Many tissues also produce IGF-1 locally.
The human IGF1 gene contains six main sections called exons. Exons are segments that can remain in the finished messenger RNA. Different starting points and different combinations of the later exons produce several transcripts. These transcripts encode precursor proteins that share the mature IGF-1 sequence but have different signal peptides or E-domains.
A signal peptide is a short starting sequence that directs a newly made protein into the cell's secretion pathway. The mature IGF-1 region contains 70 amino acids and has three internal disulphide bonds. A disulphide bond joins two cysteine residues and helps hold the protein in its folded shape. The E-domain is the extension after mature IGF-1 in the precursor.
Enzymes can process IGF-1 precursors by cutting at selected sites. Mature IGF-1 acts through the IGF-1 receptor, usually written as IGF-1R. A receptor is a protein that receives a molecular signal. IGF-1R activation can influence pathways involved in protein production, cell survival, growth and metabolism.
This system does not mean that every IGF-1 transcript produces an independently active E-peptide. Detecting RNA shows that a gene transcript is present. Detecting a precursor shows that protein was made. Establishing a separate natural peptide requires reliable measurement of that peptide in tissue or body fluid, together with evidence about how it is processed and what receptor or pathway it uses.
What is the proposed role of IGF-1Ec after mechanical loading?
The original idea was that mechanical strain or tissue damage changes local IGF1 splicing. IGF-1Ec was proposed to appear early, when damaged muscle needs to activate satellite cells. Satellite cells are muscle stem cells that can multiply and later help repair or enlarge muscle fibres.
In this model, the early Ec-related signal encourages a pool of immature cells to expand. Other IGF-1 forms then support differentiation, the process by which those cells become more specialised and join developing muscle fibres. The model is biologically plausible, but its details remain debated.
One difficulty is that muscle adaptation involves many linked signals. Exercise changes mechanical force, calcium, inflammation, energy use, hormones and blood flow. A rise in one RNA transcript does not show that it is necessary or sufficient for growth. It can be one part of a wider response.
Another difficulty is timing. A biopsy provides a snapshot from a small area of muscle. Studies sampling at two hours, six hours, two days or sixteen days can produce different results because RNA expression changes quickly. Exercise type, training status, age and the amount of muscle damage also differ between studies.
The proposed sequence is therefore a research framework, not a treatment mechanism established in patients.
When was MGF first documented?
The underlying IGF-1 gene and its alternative transcripts were studied before the name mechano growth factor became common. The modern MGF story began in the mid-1990s.
In 1996, researchers reported cloning and characterising an IGF-1 isoform from rabbit skeletal muscle exposed to stretch. The experiment altered the activity of the tibialis anterior muscle, a muscle at the front of the lower leg, and followed gene expression from two hours to six days. The transcript was related to what later became known as human IGF-1Ec.
A 1999 rabbit study examined local IGF-1 splice-variant expression after stretch and electrical stimulation. During the early 2000s, researchers reported MGF-related RNA responses in human muscle biopsies after resistance exercise. Synthetic tail-peptide experiments then examined cells and animals.
By 2010, a critical review argued that the field had moved too quickly from an RNA transcript to a presumed independent peptide. In 2014, one study reported that the proposed short natural peptide was not detected in living tissue using the methods employed and found no independent proliferative action in its C2C12 muscle-cell model. Other laboratories reported cell effects, so the disagreement has not been settled by one experiment.
Also in 2014, anti-doping researchers characterised a larger biotechnology-produced product sold as full-length MGF. Its measured structure differed from a simple 24-amino-acid tail peptide. The paper illustrates how far commercial naming had moved from one defined molecule.
| Year | Development |
|---|---|
| 1996 | A mechanically responsive IGF-1 transcript was reported in stretched rabbit muscle |
| 1999 | Further animal work examined IGF-1 splicing after muscle loading |
| 2002 | A synthetic MGF tail peptide was reported to affect mouse muscle-like cells |
| 2003 | Human biopsy research compared young and older adults after resistance exercise |
| 2007 to 2011 | Cell and animal studies examined synthetic 24-amino-acid E peptides |
| 2010 | A critical review separated the IGF-1Ec transcript from assumed MGF products |
| 2014 | A study questioned in-vivo detection of a separate tail peptide; anti-doping researchers analysed a product sold as full-length MGF |
| Current position | No approved MGF medicine or established human administration programme exists |
What is synthetic MGF E peptide made from?
The best described short research form is a 24-amino-acid chain copied from the end of the human IGF-1Ec E-domain. Its reported sequence is YQPPSTNKNTKSQRRKGSTFEEHK. The letters are one-letter codes for amino acids. For example, Y is tyrosine, Q is glutamine and K is lysine.
This chain is not mature IGF-1. It lacks the 70-amino-acid IGF-1 region and the folded structure that activates the IGF-1 receptor. It is also not the full IGF-1Ec precursor.
Some studies describe a 25-amino-acid E peptide or use different boundaries. A one-residue difference can change molecular mass, charge, enzyme sensitivity and biological activity. The sequence, terminal chemistry and salt therefore need to be reported rather than inferred from the letters MGF.
A larger full-length research product requires a different description. The 2014 anti-doping analysis found a protein with a monoisotopic mass of 12,264.9 daltons. Monoisotopic mass is the calculated mass using the lightest common isotope of each atom. The product was related to IGF-1Ec but lacked the signal and propeptide portions and contained further sequence changes. It should not be treated as chemically equivalent to the 24-amino-acid peptide.
How is MGF peptide synthesised and manufactured?
A short MGF E peptide can be made by solid-phase peptide synthesis. One end of the chain is attached to a resin, which is a solid polymer support. Protected amino-acid building blocks are joined one at a time in the required order.
Protective groups temporarily cover chemical sites that should not react during a particular step. Each cycle removes the temporary group from the growing end, activates the next amino acid and forms a peptide bond. Washing removes unused reagents and some by-products. The raw materials include protected forms of the 24 amino acids, resin, coupling reagents, bases, solvents and chemicals used to release the final chain.
After assembly, the peptide is cut from the resin and the remaining protective groups are removed. The crude product can contain shorter deletion sequences, chains with an extra residue, incompletely deprotected material, oxidised residues and residual manufacturing chemicals.
Preparative high-performance liquid chromatography, shortened to HPLC, can separate many impurities. Mass spectrometry can test whether the main component has the expected molecular mass. Sequence confirmation may use tandem mass spectrometry, in which peptide fragments help show amino-acid order. Amino-acid analysis and tests for water, counterions and residual solvents provide further information.
A full-length IGF-1Ec-related protein is too large and structurally complex to treat as the same manufacturing task. It may be produced by recombinant biotechnology, meaning that engineered living cells make the protein. The producer must then recover, purify, fold and characterise it. The mature IGF-1 region contains disulphide bonds, so correct folding and disulphide pairing matter.
Neither route automatically produces a clinical-grade medicine. For injectable material, sterility, bacterial endotoxins, particles, concentration, container integrity and stability need separate validated controls. Endotoxins are inflammatory bacterial components that can remain even when living bacteria are absent.
A label reporting 99 per cent purity is incomplete. It may refer only to the relative area of one HPLC peak. It does not establish sequence, terminal form, quantity, sterility, endotoxin level, aggregation, stability or the absence of closely related peptide impurities.
Does the body naturally make a separate MGF peptide?
This remains one of the central uncertainties.
The body clearly produces IGF1 transcripts, including the Ec form, and can make IGF-1 precursor proteins with E-domains. The disputed step is whether a stable, free MGF tail peptide matching common synthetic products is normally released in sufficient amounts to act as an independent signal.
Early models assumed that enzymes cut the unique E-domain from the precursor and that the resulting peptide had its own receptor or signalling pathway. Several cell experiments reported effects that were not blocked by an antibody against the IGF-1 receptor. That finding suggested an IGF-1R-independent route, but it did not identify a receptor.
The 2010 review found insufficient evidence for a naturally occurring MGF peptide with a defined independent role. The 2014 Fornaro study used antibodies and mass-spectrometry-related methods and reported that the short proposed product was not detected in vivo. In its C2C12 myoblast experiments, the short C-terminal peptide did not independently increase proliferation.
Other laboratories reported proliferation, migration or survival effects with synthetic peptides. Differences in sequence, concentration, cell type, culture conditions and assay design may contribute. A synthetic molecule can also have laboratory activity even if an identical free peptide is not normally present in the body.
The careful conclusion is not that every MGF experiment is invalid. It is that results from synthetic E peptides must be described as results from those peptides, not as proof of a natural circulating MGF hormone.
What human evidence exists?
Human MGF research is mainly muscle-biopsy research. Participants exercised, and investigators measured IGF-1 splice-variant mRNA or related proteins in tissue. These studies answer a question about the body's response to loading. They do not answer what an administered MGF product does.
Biopsy means removing a small tissue sample for analysis. Reverse-transcription polymerase chain reaction, often shortened to RT-PCR, converts RNA into DNA and amplifies selected sequences so researchers can estimate gene expression. A larger PCR signal can indicate more target mRNA in the sample. It does not measure a whole-body peptide concentration or clinical benefit.
The studies were generally small and used different exercise protocols, time points and participant groups. Results were not completely consistent. Some found a rapid increase in MGF mRNA. Others found no significant change at the sampled time.
No Phase 1 trial of a defined MGF peptide was identified. Phase 1 is the early stage of clinical testing that usually examines safety, tolerability and how a product moves through the body. There is also no controlled Phase 2 or Phase 3 programme establishing treatment benefit.
What did the young and older adult resistance study find?
A 2003 study included eight younger adults aged 25 to 36 and seven older adults aged 70 to 82. Participants completed ten sets of six one-leg knee extensions at 80 per cent of their one-repetition maximum. One-repetition maximum is the greatest load a person can lift once with correct technique in the study setting.
Researchers took quadriceps biopsies from the exercised and control legs two and a half hours after exercise. MGF mRNA was higher in the exercised muscle of the younger group. The older group did not show the same statistically significant response. Statistically significant means the observed difference met the study's predefined statistical threshold; it does not show that the change was large enough to improve health or function.
The paper helped develop the idea that ageing may change local IGF-1 splicing after resistance exercise. It did not administer MGF, measure long-term muscle gain or show that replacing an assumed MGF deficit would improve outcomes.
What did later human exercise studies find?
A 2008 study enrolled nine younger people aged 20 to 27 and eight older people aged 67 to 75. They completed 60 minutes of reverse-pedal eccentric cycling. Eccentric exercise places force on muscle while it lengthens. Quadriceps biopsies were taken before and two and a quarter hours after the session. Mean MGF mRNA increased in both age groups, while IGF-1Ea mRNA did not significantly change.
This result did not reproduce the simple idea that older muscle cannot increase MGF-related expression. The protocol, participants and sampling time differed from the earlier study.
A 2009 experiment studied ten healthy men after exercise designed to cause muscle damage. Biopsies were taken before exercise and at six hours, two days, five days and sixteen days. MGF mRNA increased rapidly and temporarily. IGF-1Ea and IGF-1Eb showed a later, longer pattern. The same paper included a separate C2C12 mouse muscle-cell experiment with synthetic MGF E peptide. The human and cell parts should not be blended together.
A study of 13 men compared two resistance-exercise intensities and found increased MGF mRNA two hours after both. A later study of eight strength-trained men reported increased IGF-1Ea and MGF mRNA 48 hours after heavy leg press and squat exercise.
Not every experiment found the same response. Differences in exercise, muscle sampled, assay, timing and prior training make direct comparison difficult. The overall record supports mechanically responsive IGF1 expression, but it does not establish one universal time course or prove that more MGF mRNA causes more muscle growth.
Did growth hormone research prove an MGF treatment effect?
No. A study in healthy older men examined recombinant human growth hormone, resistance training and muscle IGF-1 transcripts. Recombinant means produced by engineered cells.
Five weeks of resistance training was associated with increased MGF, IGF-1Ea and IGF-1Eb mRNA. Growth hormone changed aspects of IGF-1 expression, and the combination affected the measured transcript pattern. These were molecular observations in muscle tissue.
The administered substance was growth hormone, not MGF. The experiment cannot establish the benefit or safety of an MGF product. It also does not show that changing a transcript is the reason for any change in muscle size or strength.
This is a common evidence-transfer error. A paper containing the term MGF may be used to support a product even when no participant received that product.
What did the muscle-cell studies find?
Several experiments used C2C12 cells. These are mouse cells that can multiply as myoblasts and then differentiate into muscle-like fibres under selected culture conditions. A myoblast is an immature muscle-forming cell.
An early paper reported that a synthetic MGF E-domain peptide increased C2C12 myoblast proliferation and delayed terminal differentiation. Proliferation means an increase in cell number. Terminal differentiation means the later step in which immature cells stop dividing and develop a specialised muscle-cell programme.
The 2009 human exercise-damage paper also tested synthetic E peptide in C2C12 cells. Its proliferative effect was not blocked by an IGF-1 receptor-neutralising antibody, and it did not activate Akt in the same way as mature IGF-1. Akt is a signalling protein involved in cell survival, metabolism and growth.
A 2014 paper reached a less supportive conclusion and reported no independent proliferative effect from the proposed C-terminal peptide. A later comparison of full IGF-1Ec, mature IGF-1 and E peptide found that the E peptide could not reproduce every effect of the full precursor.
Cell culture gives researchers control over concentration and timing. It also removes the compound from digestion, immune responses, blood distribution and many tissue interactions. Concentrations placed directly on cells cannot be converted into an administration level for a person.
What did research using human muscle progenitor cells show?
Human muscle progenitor cells are early cells capable of contributing to muscle formation. They are studied outside the body after being isolated from donated tissue.
A 2007 study used a 24-amino-acid peptide called MGF-Ct24E with human muscle progenitor cells and a mouse transplantation model. The researchers reported changes in proliferation and differentiation and improved engraftment after the human cells were transplanted into mice. Engraftment means that transplanted cells survive and become established in the recipient tissue.
A 2011 paper examined satellite cells from neonatal, young-adult and older human donors. The synthetic peptide increased the proliferative lifespan and delayed senescence in cells from neonatal and young adults, with a weaker response in older-donor cells. Senescence is a state in which cells remain alive but stop dividing and change their behaviour.
These are not trials in people. Donor age, cell culture conditions and transplantation into an animal are research models. They can generate hypotheses about cell biology, but they do not show that administering MGF restores ageing muscle.
What animal research exists?
Animal research extends beyond skeletal muscle, but it remains preclinical. Preclinical means research conducted before adequate testing in people, usually in cells or animals.
In a sheep model of heart attack, researchers created small areas of heart damage using microspheres and compared mature IGF-1, an MGF E-domain peptide, full MGF and control material. Microspheres are tiny particles used in this experiment to block small blood vessels. The E-domain group showed better short-term cardiac measurements and less damaged tissue in parts of the experiment. The animals were assessed after eight days. This does not establish treatment of human heart attack.
Other studies examined bone defects, rat Achilles tendon repair, rat bone-marrow stem-cell movement and spinal-disc degeneration. Some reported favourable tissue or cell findings. The models used controlled injuries, specific experimental compounds and short observation periods. They do not show reliable healing of human sport injuries.
Local-delivery work has also placed unmodified MGF peptide inside polyethylene-glycol-based hydrogel microrods. A hydrogel is a water-containing polymer network used as a delivery material. This is sometimes misdescribed as PEG-MGF. The peptide was physically loaded into a PEG-containing device; polyethylene glycol was not necessarily covalently attached to the peptide.
Does MGF build muscle in people?
No controlled human trial has established that an administered MGF peptide increases muscle mass, strength or physical function.
The strongest human evidence is that an IGF-1Ec-related RNA signal can change after exercise. That is not the same as testing a drug. A muscle can increase a transcript as part of normal adaptation without an externally supplied copy reproducing the process.
The cell evidence concerns cell number or differentiation under culture conditions. More myoblasts in a dish do not automatically produce stronger adult muscle. Muscle growth in a person depends on training, protein balance, nerve activation, hormones, blood supply and integration of new nuclei into functioning fibres.
The animal work uses different sequences, delivery methods and injury models. It can support further investigation, not a claim of human muscle gain.
Does MGF heal tendon or other injuries?
The rat Achilles tendon paper reported findings after a synthetic 25-amino-acid peptide in an experimental injury model. Researchers can create a standardised injury in animals, control timing and collect the entire tissue for analysis. Human tendon injuries vary in location, severity, loading history, age and treatment.
No controlled human trial shows that an MGF product speeds tendon healing, reduces pain or restores function. Similar limits apply to claims about ligament, cartilage, bone, nerve and heart repair.
Healing is not one outcome. A study may measure collagen organisation, cell number, tissue strength, imaging, pain or return to activity. A favourable microscopic finding does not prove faster safe return to sport.
Does MGF reduce fat or improve metabolism?
Direct evidence is lacking. MGF is sometimes grouped with growth hormone or IGF-1 compounds and then credited with their proposed metabolic effects. This is not valid evidence transfer.
The short E peptide lacks the mature IGF-1 region, and its receptor remains uncertain. Human expression studies did not test fat loss. Animal repair studies were not weight-management trials.
No controlled human evidence establishes effects on body weight, visceral fat, appetite, glucose control, insulin sensitivity or blood lipids.
What safety information is available?
There is no adequate human administration record from which to calculate common adverse effects, rare harms or longer-term risks. Absence of reports is not evidence of safety when exposure has not been systematically studied.
Possible concerns depend on the material. A short E peptide may have different targets from a full IGF-1Ec-related protein. A full product containing mature IGF-1 could activate IGF-1 receptors and may carry risks associated with excessive or misplaced growth signalling. Product impurities can add separate risks.
Laboratory findings involving proliferation require careful interpretation. Proliferation is useful during repair, but uncontrolled growth signalling is also relevant to cancer biology. Studies have reported IGF-1Ec-related expression in some tumour tissues and cell models. They do not prove that MGF causes cancer in people, but they make broad claims of harmless tissue growth inappropriate.
Injected peptides can trigger immune responses. Immunogenicity means the ability to provoke antibodies or other immune reactions. Sequence impurities, aggregates and altered proteins can increase that risk. Allergic reactions, loss of activity or antibodies that cross-react with related natural proteins are theoretical concerns until studied.
Sterility, endotoxin contamination, incorrect concentration and mislabelling are product risks rather than effects of the intended molecule. They matter when a substance is not supplied as an approved medicine with validated manufacturing and surveillance.
Is MGF approved as a medicine?
No. MGF peptide is not an FDA-approved medicine, and we did not identify an EMA-authorised MGF product.
FDA approval applies to a specific active ingredient, formulation, manufacturer and medical use supported by an application. A PubMed paper, chemical listing, patent or compounding nomination is not approval.
Compounded medicines are prepared for particular patients under legal conditions. They are not FDA approved, and FDA does not assess them before marketing in the same way as approved products. The regulatory position of a bulk ingredient can also change. Readers should not infer approval from availability.
Is MGF prohibited in sport?
Yes. The World Anti-Doping Agency, commonly called WADA, includes mechano growth factors within the prohibited growth-factor category. The prohibition applies at all times, meaning both in and out of competition for athletes covered by the World Anti-Doping Code.
Anti-doping rules do not depend on whether a substance is approved, effective or correctly labelled. Athletes are responsible for prohibited substances found in their samples. A research-only label does not create an exemption.
How does MGF compare with IGF-1, IGF-1 LR3 and PEG-MGF?
| Feature | MGF or MGF E peptide | Mature IGF-1 | IGF-1 LR3 | PEG-MGF |
|---|---|---|---|---|
| Typical meaning | IGF-1Ec transcript, precursor or short E-domain peptide | Natural 70-amino-acid hormone | Engineered 83-amino-acid IGF-1 analogue | MGF-related peptide covalently linked to polyethylene glycol |
| Main evidence | Human expression studies plus cell and animal experiments | Extensive physiology and condition-specific medical evidence | Mainly laboratory and animal research | No identified human exposure data and very limited defined preclinical evidence |
| Receptor | Uncertain for short E peptide; full precursor contains mature IGF-1 | IGF-1 receptor | IGF-1 receptor | Depends on peptide identity and effect of PEG attachment |
| Approved medicine | No | Defined recombinant IGF-1 medicines exist for narrow indications | No | No |
| Key problem | One name is used for several materials | Effects depend on clinical context and product | Long action claims exceed direct evidence | Product is not chemically standardised in the public evidence |
The IGF-1 LR3 guide explains another research compound commonly grouped with MGF. PEG-MGF needs separate evaluation because attaching polyethylene glycol changes molecular size, distribution and potentially biological activity.
What product-quality questions matter?
A meaningful assessment starts with identity:
- Is the material the 24-amino-acid E peptide, a 25-amino-acid construct or a longer protein?
- What is the exact sequence and terminal chemistry?
- Does the material include mature IGF-1?
- If it is recombinant, is the protein correctly folded and are disulphide bonds confirmed?
- Which salt and counterions are present?
- Are deletion sequences, oxidation products and aggregates measured?
- Does the container hold the stated quantity?
- Has stability been demonstrated for the stated conditions?
- For an injectable product, are sterility, endotoxins and particles controlled by validated methods?
The name MGF answers none of these questions. Two products with that label can contain molecules of very different size and biological potential.
What claims are not established?
Current evidence does not establish administered MGF for:
- Building muscle or increasing strength in people.
- Improving exercise performance, recovery or endurance.
- Healing tendon, ligament, cartilage, bone, muscle or nerve injuries.
- Treating age-related muscle loss.
- Reducing body fat or increasing fat breakdown.
- Improving glucose regulation or insulin sensitivity.
- Protecting the human heart or brain after injury.
- Producing local tissue growth without wider effects.
- Providing IGF-1 benefits without IGF-1-related risks.
- Preventing ageing or extending life.
Several claims begin with a genuine experiment. The problem is the jump from RNA in a biopsy, cells in a dish or an animal injury model to a commercial peptide and a human outcome.
What would stronger evidence require?
Researchers would first need a single defined product. The sequence, length, terminal chemistry, salt, purity, aggregates, stability and biological activity would need to be established. A longer protein would also require folding and disulphide-bond confirmation.
Before human exposure, toxicology should examine intended and unintended targets, immune responses, organ effects and any growth-related concerns. Species selection would need care because human and rodent IGF-1 splice nomenclature differs.
An early human study would assess pharmacokinetics, pharmacodynamics, tolerability and antibodies. Pharmacokinetics describes absorption, distribution, breakdown and removal. Pharmacodynamics describes what the product does to the body.
Later trials would require a defined condition and patient-important outcomes. A muscle-injury trial might measure pain, validated function, time to return and reinjury, not only an RNA marker. A muscle-loss trial would need strength and physical performance as well as imaging-based lean mass.
Random assignment would use chance to create comparable groups. A placebo would provide an inactive comparison. Blinding would keep participants and assessors unaware of allocation where possible. Adequate follow-up would be needed to detect delayed immune or growth-related effects.
This is a much larger evidence programme than showing that a peptide changes cell number in culture.
Frequently asked questions
What does MGF stand for?
MGF stands for mechano growth factor, a name given to an IGF-1-related form reported to respond to mechanical loading.
Is MGF one molecule?
Not in common usage. The name can refer to IGF-1Ec mRNA, its larger precursor protein or a synthetic 24 or 25-amino-acid E-domain peptide.
Is MGF a natural peptide?
The body produces the IGF-1Ec transcript and related precursor. Whether it releases a stable independent short peptide matching commercial MGF products remains disputed.
Is MGF the same as IGF-1?
No. The short MGF E peptide does not contain mature 70-amino-acid IGF-1. A full IGF-1Ec precursor does contain the mature IGF-1 region plus an extension.
Is MGF the same as IGF-1 LR3?
No. IGF-1 LR3 is an engineered 83-amino-acid IGF-1 analogue designed to interact differently with IGF-binding proteins.
Is MGF the same as PEG-MGF?
No. PEG-MGF is described as an MGF-related peptide chemically attached to polyethylene glycol. That attachment changes the product and requires separate evidence.
Does exercise increase MGF?
Some human biopsy studies found increased IGF-1Ec or MGF mRNA after resistance, eccentric or muscle-damaging exercise. Results depend on protocol and sampling time.
Did people receive MGF in those exercise studies?
No. Participants exercised, and researchers measured the body's gene-expression response in muscle samples.
Does MGF build muscle?
No controlled human administration trial has shown increased muscle mass, strength or function from an MGF product.
Does MGF heal tendons?
A rat Achilles tendon experiment reported findings with a synthetic peptide, but no controlled human trial has established tendon healing.
Is the 24-amino-acid peptide full-length MGF?
No. It is a short sequence copied from the unique E-domain tail. Full IGF-1Ec-related proteins are much larger.
What is mRNA?
Messenger RNA is a temporary molecular copy that cells use when making a protein. Measuring mRNA does not prove that a particular free peptide was produced.
Has an MGF receptor been identified?
No clearly accepted specific receptor for the short MGF E peptide has been established.
Is MGF FDA approved?
No. There is no FDA-approved MGF medicine.
Is MGF prohibited in sport?
Yes. WADA includes mechano growth factors within its prohibited growth-factor category.
Are research concentrations or animal levels personal dosages?
No. Laboratory concentrations and animal administration levels document experiments. They cannot be converted into personal instructions.
Sources
Research reviewed through September 2026.